The FDA has approved Janssen Pharmaceuticals' supplemental new drug application for NUCYNTA, according to CSL Recruitment.
The drug comes in extended release tablets, which strive to manage the neuropathic pain associated with diabetic peripheral neuropathy in adults.
The medication also aims to help adults with severe chronic pain resulting from extended use of an opioid analgesic.
Clinical studies found NUCYNTA use resulted in a one-point reduction in pain intensity during a three week treatment period and substantial pain improvement after 12 weeks.
More Articles on Anesthesia:
Sleep Apnea Diagnostic and Portable Anesthesia Systems Are Fastest Growing Markets
10 Recent Pain Management & Anesthesia Device Recalls
AcelRx Begins Final Phase of Testing for Patient-Controlled Analgesia System
The drug comes in extended release tablets, which strive to manage the neuropathic pain associated with diabetic peripheral neuropathy in adults.
The medication also aims to help adults with severe chronic pain resulting from extended use of an opioid analgesic.
Clinical studies found NUCYNTA use resulted in a one-point reduction in pain intensity during a three week treatment period and substantial pain improvement after 12 weeks.
More Articles on Anesthesia:
Sleep Apnea Diagnostic and Portable Anesthesia Systems Are Fastest Growing Markets
10 Recent Pain Management & Anesthesia Device Recalls
AcelRx Begins Final Phase of Testing for Patient-Controlled Analgesia System